Abetimus

Identification

Name
Abetimus
Accession Number
DB06662
Type
Biotech
Groups
Investigational
Biologic Classification
Nucleic Acid Based Therapies
Oligonucleotides
Description

Abetimus is an immunosuppressant developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Abetimus sodiumF5Y7739G6U169147-32-4Not applicable
International/Other Brands
Riquent
Categories
UNII
P3UVQ22SHK
CAS number
167362-48-3

Pharmacology

Indication

Investigated for use/treatment in kidney disease and systemic lupus erythematosus.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Abetimus is combined with Anthrax immune globulin human.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Abetimus is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Abetimus is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Abetimus.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Abetimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Abetimus is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Abetimus.Approved
FingolimodAbetimus may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Abetimus is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Abetimus is combined with GI-5005.Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Abetimus is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Abetimus is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Abetimus is combined with Human rabies virus immune globulin.Approved
INGN 201The risk or severity of adverse effects can be increased when Abetimus is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Abetimus is combined with INGN 225.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Abetimus is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
LeflunomideThe risk or severity of adverse effects can be increased when Abetimus is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Abetimus is combined with Natalizumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Abetimus.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Abetimus.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Abetimus is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abetimus.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Abetimus is combined with Rindopepimut.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Abetimus.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Abetimus is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Abetimus is combined with Rubella virus vaccine.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Abetimus is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Abetimus is combined with Salmonella typhi ty21a live antigen.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Abetimus.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Abetimus is combined with SRP 299.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Abetimus.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Abetimus is combined with Tecemotide.Investigational
TG4010The risk or severity of adverse effects can be increased when Abetimus is combined with TG4010.Investigational
TofacitinibAbetimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Abetimus.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Abetimus is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Abetimus is combined with Yellow Fever Vaccine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Abetimus: Abetimus sodium, LJP 394. BioDrugs. 2003;17(3):212-5. [PubMed:12749759]
  2. Wallace DJ: Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs. 2001 Jan;10(1):111-7. [PubMed:11116284]
External Links
Wikipedia
Abetimus
ATC Codes
L04AA22 — Abetimus

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnDiagnosticSystemic Lupus Erythematosus (SLE)1
3CompletedTreatmentAutoimmune Diseases / Immunologic Diseases / Lupus Glomerulonephritis / Nephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
3TerminatedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:46 / Updated on March 02, 2018 05:28